

1 **Validation of multiplex steroid hormone measurements in prostate cancer using**  
2 **plasma for multimodality biomarker studies**

3 Gido Snaterse<sup>1,a</sup>, Lisanne F van Dessel<sup>2,a</sup>, Angela E Taylor<sup>3</sup>, Jenny A Visser<sup>1</sup>, Wiebke Arlt<sup>3</sup>, Martijn P  
4 Lolkema<sup>2</sup>, Johannes Hofland<sup>1,\*</sup>

5 1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, University Medical Center  
6 Rotterdam, Rotterdam, The Netherlands

7 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, University Medical  
8 Center Rotterdam, Rotterdam, The Netherlands

9 3. Institute of Metabolism and System Research, University of Birmingham, Birmingham, United  
10 Kingdom

11 <sup>a</sup>These authors contributed equally to this work.

12 \*Corresponding author

13 Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, Rg5, Dr.  
14 Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Tel.: +31 10 704 0446.

15 E-mail: [j.hofland@erasmusmc.nl](mailto:j.hofland@erasmusmc.nl)

16

17 **Running title:** Multiplex steroid measurements in prostate cancer

18 **Key words:** Steroids, Androgens, Testosterone, CellSave, LC-MS/MS

19



21 **General Abbreviations**

22	ANOVA	Analysis of variance
23	CRPC	Castration-resistant prostate cancer
24	CS	CellSave Preservative
25	CTC	Circulating tumour cell
26	ctDNA	circulating tumour DNA
27	DHEA	Dehydroepiandrosterone
28	DHT	5 $\alpha$ -dihydrotestosterone
29	HC	Healthy Control
30	LC-MS/MS	Liquid-chromatography tandem mass spectrometry
31	LLOQ	Lower limits of quantification
32	mCRPC	Metastatic castration-resistant prostate cancer
33	MS	Mass spectrometry
34	MSP	Mechanically-separated plasma
35	MTBE	Methyl-tert butyl ether
36	PC	Prostate cancer
37	PBS-BSA	phosphate-buffered saline with bovine serum albumin

38

39

40 **ABSTRACT**

41 **Background**

42 Steroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies  
43 focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid  
44 measurements are sensitive to bias caused by matrix effects, thus assessing potential matrix effects is an  
45 important step in combining circulating tumour DNA analysis with hormone status.

46 **Methods**

47 We investigated the accuracy of multi-steroid hormone profiling in mechanically-separated plasma  
48 (MSP) samples and in plasma from CellSave Preservative (CS) tubes, that are typically used to obtain  
49 circulating tumour DNA (ctDNA), compared to measurements in serum. We performed multiplex steroid  
50 profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in samples obtained from  
51 ten healthy controls and ten castration-resistant prostate cancer (CRPC) patients.

52 **Results**

53 Steroid measurements were comparable between MSP and serum. A small but consistent decrease of 8  
54 – 21% compared to serum was observed when using CS plasma, which was considered to be within the  
55 acceptable margin. The minimal residual testosterone levels of CRPC patients could be sensitively  
56 quantified in both MSP and CS samples.

57 **Conclusions**

58 We validated the use of MSP and CS samples for multi-steroid profiling by LC-MS/MS. The optimised use  
59 of these samples in clinical trials will allow us to gain further insight into the steroid metabolism in PC  
60 patients.

## 61 INTRODUCTION

62 Prostate cancer (PC) is a steroid-hormone dependent disease where androgens play a pivotal role in the  
63 evolution of the disease. Targeting the androgen receptor (AR) signalling pathway through androgen  
64 deprivation therapy (ADT) in locally advanced and metastatic PC is a highly effective way to inhibit  
65 tumour growth<sup>1</sup>. However, tumour cells will eventually become resistant to these low androgen  
66 concentrations and show disease progression. Resistance mechanisms include AR modifications, like  
67 mutations and overexpression<sup>2,3</sup>, and changes in androgen biosynthesis and metabolism, thereby  
68 increasing intratumoural androgen availability<sup>4-6</sup>. The continued importance of the androgen signalling  
69 pathway in castration-resistant prostate cancer (CRPC) is underlined by the survival benefits observed  
70 with second-line therapies such as the anti-androgen enzalutamide and adrenal steroidogenesis  
71 inhibitor abiraterone<sup>7-10</sup>. Circulating steroid levels are measured to verify efficacy of hormonal  
72 treatment and have a prognostic value in patients with PC<sup>11-13</sup>.

73 The assessment of circulating steroid hormones relies heavily on sensitive, specific and accurate  
74 measurement techniques, especially at castrate levels. Liquid chromatography-tandem mass  
75 spectrometry (LC-MS/MS) combines multi-steroid profiling capabilities with superior sensitivity and  
76 specificity<sup>14,15</sup> over older techniques<sup>16,17</sup>, while maintaining high sample throughput<sup>18,19</sup>. Multi-steroid  
77 assays for LC-MS/MS have been successfully developed in recent years to improve the detection and  
78 diagnosis of disorders associated with abnormal steroid hormones concentrations<sup>20-23</sup>.

79 Steroid measurements are predominantly performed in serum samples. Previous LC-MS/MS studies  
80 have shown that steroids can be quantified reliably across different blood matrices<sup>24-26</sup>, but there are  
81 differences observed between plasma and serum, use of glass or plastic tubes in the analytic process, or  
82 when using tubes with different stabilizing agents or with gel-separators for blood collection<sup>24-29</sup>.

83 Consequently, alternative collection tubes and extraction methods must be validated before they can  
84 reliably be used for steroid profiling.

85 The use of CellSave (CS) Preservative tubes in population- and patient-based cohorts has grown as this  
86 specialised 'cell-stabilizing' blood collection tube preserves both circulating tumour cells (CTCs) and cell-  
87 free circulating tumour DNA (ctDNA)<sup>30,31</sup>. These biomarkers allow for the assessment of tumour cell  
88 genomic characteristics such as genomic instability in these patients<sup>32</sup>. These samples are now  
89 extensively collected in (cancer) biobanks and could potentially also be used to measure patient steroid  
90 profiles.

91 Mechanical blood separation methods are similarly gaining popularity in clinical chemistry due to their  
92 easy applicability compared to the use of a separation gel. The BD Vacutainer® Barricor™ is a  
93 mechanically-separated plasma (MSP) tube, and it has shown no obvious bias in steroid hormone  
94 measurements versus a gel-based plasma tube in a single study<sup>33</sup>, but this was confined to a select  
95 number of five steroids, warranting further investigation.

96 In this study, we aimed to determine if plasma obtained with MSP and CS tubes is suitable for multiplex  
97 steroid profiling, which, if confirmed, would streamline biomaterial collection for ctDNA and steroid  
98 profiling in cancer patients to the use of a single tube. To this end, we performed LC-MS/MS analysis on  
99 plasma samples obtained with MSP and CS tubes in comparison to serum obtained with standard SST™ II  
100 Advance Vacutainer® tubes, collecting blood from healthy control (HC) subjects and patients with  
101 metastatic CRPC (mCRPC).

102

## 103 **MATERIALS AND METHODS**

### 104 *Subjects*

105 At the Erasmus MC Cancer Institute in Rotterdam, The Netherlands, healthy controls (HCs) and patients  
106 were included within study EMC-2016-761, which was approved by the medical ethical committee of  
107 our institute. HCs were all adult male subjects. Patients were adult subjects with mCRPC treated with  
108 ADT. Patients were eligible to start treatment with or were currently treated with second-line hormonal  
109 therapy (abiraterone with prednisone, enzalutamide or apalutamide). For all subjects the following  
110 exclusion criteria were applied: 1) an endocrine disease with altered activity of the hypothalamic-  
111 pituitary-adrenal or hypothalamic-pituitary-gonadal axis; and 2) the use of medications, excluding those  
112 used to treat PC, that interfered with circulating steroid levels or dysregulated the hypothalamic-  
113 pituitary-adrenal or hypothalamic-pituitary-gonadal axis. All subjects provided written informed consent  
114 before any study procedure.

### 115 *Samples*

116 Blood was collected from HCs and mCRPC patients in SST™ II Advance Vacutainer® (serum; BD, Franklin  
117 Lakes, NJ, USA), Vacutainer® Barricor™ (BD) and CellSave Preservative (Menarini Silicon Biosystems Inc,  
118 Huntington Valley, PA, USA) blood collection tubes. All samples were processed within 96 hours after  
119 blood collection. All tubes were centrifuged at 1,711g for 10 minutes at room temperature. Plasma from  
120 CS tubes was subsequently centrifuged at 12,000g for 10 minutes at 4°C. Samples were stored at -80°C  
121 until extraction.

### 122 *Steroid extraction*

123 Calibration series (0.25 ng/mL – 500 ng/mL for HC, and 0.01 ng/mL – 500 ng/mL for mCRPC) were  
124 prepared in phosphate buffered saline (PBS) with 0.1% bovine serum albumin (BSA) or in charcoal-

125 stripped pooled human serum (Goldenwest Diagnostics, Temecula, CA, USA). Steroids investigated were  
126 17-hydroxyprogesterone, androstenedione, cortisol, cortisone, corticosterone, dehydroepiandrosterone  
127 (DHEA), dihydrotestosterone (DHT) and testosterone. The stripped-serum calibration series was used to  
128 quantify all steroids with the exception of androstenedione, due to a high background signal in stripped  
129 serum but not in PBS-BSA. An internal standard solution was prepared in methanol/water 50/50 with  
130 equal concentrations (1 µg/mL) of the following deuterated steroids: 17-hydroxyprogesterone-d8,  
131 cortisol-d4, corticosterone-d8, DHEA-d6, DHT-d3, testosterone-d3. All steroids were obtained from  
132 Sigma Aldrich, UK.

133 400 µL of sample was transferred to hexamethyldisilazane-treated (Thermo Fisher) glass tubes (VWR,  
134 Amsterdam, The Netherlands). 20 µL of the internal standard solution was added and all samples were  
135 thoroughly vortexed. Liquid-liquid extraction was performed as previously described<sup>34</sup> by adding 2 mL  
136 methyl-tert butyl ether (MTBE, Sigma Aldrich, Zwijndrecht, The Netherlands) to each tube and vortexing.  
137 The samples were left at room temperature for 30 minutes to allow phase separation. The upper  
138 organic layer was transferred and the MTBE was evaporated under nitrogen at 50° C. The samples  
139 underwent a second liquid-liquid extraction with 2 mL MTBE. Samples were reconstituted in 125 µL LC-  
140 MS grade 50% methanol (CHROMASOLV, Sigma Aldrich, Zwijndrecht, The Netherlands) before  
141 measurement.

142 *Steroid analysis by tandem mass spectrometry*

143 Steroid concentrations were measured by mass spectrometry (Xevo TQ-XS, Waters, Milford, MA, USA)  
144 after injection of 20 µL sample volume and separation on an ACQUITY uPLC (Waters) with a Waters HSS  
145 T3 column (2.1 mm x 50 mm, 1.8 µm, Waters)<sup>35-39</sup>. The mobile phases consisted of water (A) and  
146 methanol (B) both with 0.1% formic acid and a 5-minute linear gradient was used (45 – 75% B) with a  
147 flow rate of 0.6 mL/min. The multiple reaction monitoring settings and retention times of the LC-MS/MS  
148 method were previously reported<sup>36,38,39</sup>. The method used represents an optimisation of these methods,  
149 steroid transitions were re-tuned for optimum response. The updated reaction settings, retention times  
150 and lower limits of quantification (LLOQ) can be found in **Supplementary Table 1** and a representative  
151 chromatogram can be found in **Supplementary Figure 1**.

152 Steroids were quantified against the linear calibration series relative to an internal standard and were  
153 only included in the final analysis if the calibration series  $R^2$  was > 0.99 and appropriate lower limits of  
154 quantification were reached. The LLOQ was set to the lowest calibration concentration that had a clearly  
155 defined peak and a signal-to-noise ratio > 10. Samples with concentrations below the LLOQ were  
156 detectable, but quantification was less accurate.

157 *Statistics*

158 LC-MS/MS raw data was processed using MassLynx (v4.1, Waters). Statistical analysis was performed  
159 using GraphPad Prism (Version 6). Normality of the data was analysed with a D'Agostino & Pearson's  
160 test. Comparisons of steroid hormone concentrations between the blood collection tubes were  
161 performed with Bland-Altman difference analysis and repeat measurements 1-way ANOVA with post-  
162 hoc Dunnett's test. Correlations in hormone levels were determined by Deming regression. Group  
163 concentrations and differences are shown as mean ± SD, unless specified otherwise. P values were  
164 considered significant if <0.05.

165 **RESULTS**

166 **Comparison of blood collection tubes**

167 Baseline characteristics of the study participants are shown in **Table 1**. Circulating steroid levels of 8  
168 steroids were determined by LC-MS/MS in plasma collected with CS and MSP tubes, respectively, and  
169 serum, all collected from 10 HCs and 10 mCRPC patients. Quantification and concentration ranges for  
170 the steroids are reported in **Table 2**. Most steroids could be quantified in HCs at the level of the lowest  
171 calibration sample (0.25 ng/mL), with the exception of androstenedione (0.5 ng/mL), DHEA (1 ng/mL)  
172 and DHT (1 ng/mL). Serum values below the LLOQ were detected for DHEA (HC: n = 1, mCRPC: n = 4), 17-  
173 hydroxyprogesterone (mCRPC: n = 2) and testosterone (mCRPC: n = 2) and excluded from further  
174 analysis.

175 The values observed in MSP samples were comparable to those found in serum samples for most  
176 steroids. The only exception was DHEA, which was higher ( $21.3 \% \pm 32.9 \% p < 0.05$ ) in MSP samples than  
177 in serum (**Figure 1**). In CS samples, significantly lower concentrations compared to serum samples were  
178 observed for corticosterone ( $-16.2 \% \pm 15.2 \% , p < 0.001$ ), 17-hydroxyprogesterone ( $-9.4 \% \pm 19.9 \% ,$   
179  $p < 0.05$ ), cortisol ( $-13.2 \% \pm 13.0 \% , p < 0.001$ ), cortisone ( $-14.4 \% \pm 13.1 \% , p < 0.001$ ), and  
180 androstenedione ( $-18.4 \% \pm 13.6 \% , p < 0.001$ ). No significant differences were found for DHEA compared  
181 to serum.

182 Similar steroid concentrations between HC and mCRPC subjects were observed for corticosterone,  
183 cortisol and cortisone (**Figure 2**). Lower concentrations were observed for 17-hydroxyprogesterone,  
184 androstenedione, DHEA and testosterone in mCRPC subjects. This was likely due to a combination of  
185 castration (testosterone) and age-related effects, as the mCRPC subjects were older than the healthy  
186 control subjects.

187 Circulating androgen concentration in mCRPC patients are >10 fold lower than in healthy men due to  
188 ADT, requiring highly sensitive techniques to accurately measure residual androgens. Therefore, the  
189 calibration series was expanded to include lower concentrations (0.01 – 0.25 ng/mL) to allow  
190 quantification of castrate testosterone levels. Accurate quantification at low concentration was  
191 achieved, with an analytic LLOQ for testosterone of 0.1 nmol/L. Similar to the other steroids, lower  
192 testosterone concentrations compared to serum were detected in CS samples, but not in MSP samples,  
193 at normal HC concentrations ( $-11.5\% \pm 2.8\%$ ,  $p < 0.001$ ) and at castrate concentrations ( $-16.9\% \pm 24.3\%$ ,  
194  $p < 0.05$ ) (**Figure 1**). Low signal-to-noise ratios limited the reliability of DHT quantification which could not  
195 be accurately quantified in the mCRPC subjects with our assay.

#### 196 **Correlation of steroid measurements between matrices**

197 The correlations between results obtained in MSP and CS samples compared to those results obtained in  
198 serum were independently determined by Deming regression (**Figure 3**). For DHT analysis only HC  
199 samples were included. Corticosterone, DHEA and testosterone were normally distributed after log-  
200 transformation. Significant correlations (all  $p < 0.001$ ) between both matrices and serum was observed  
201 for 17-hydroxyprogesterone, androstenedione, corticosterone, cortisol, cortisone, DHEA and  
202 testosterone. The analysis also revealed a poor correlation for DHT between CS and serum ( $R^2 = 0.60$ )  
203 and between MSP and serum ( $R^2 = 0.45$ ), whereas steroid concentrations measured in MSP and CS  
204 samples, respectively, correlated more closely ( $R^2 = 0.89$ ,  $y = 0.89x + 0.15$ ) (data not shown).

205

## 206 DISCUSSION

207 In this study, we investigated whether MSP- or CS-derived plasma, samples that are abundantly present  
208 in biobanks obtained from PC patients, are suitable for multiplex steroid profiling by LC-MS/MS. We  
209 compared them to the current standard collection method using serum samples collected with SST™ II  
210 Advance Vacutainers®. We showed that measurements in MSP are equal to serum. When collecting  
211 plasma in CS tubes, steroid concentrations were 8-21% lower than measurements using serum or MSP.  
212 The Guideline on Bioanalytical Method Validation (2011) of the European Medicines Agency advises that  
213 accuracy must be within 15 % of the nominal concentration and within 20 % at the LLOQ<sup>40</sup>. The  
214 decreases observed for most steroids in CS plasma, using serum as a reference, were within this  
215 acceptable range (**Table 2**). Therefore, we conclude that CS plasma samples are suitable for steroid  
216 profiling, which can be combined with analysis of CTCs or ctDNA. However, caution is advised when  
217 interpreting results obtained in CS plasma samples against reference values that were obtained in  
218 serum, and direct comparison to samples collected in other tubes should be avoided. Nevertheless,  
219 these findings may reduce patient burden and open up the possibility to undertake detailed steroid  
220 profiling of large collections of biomaterial already collected for ctDNA analysis.

221 In this study, most steroids could be quantified accurately within the range of the calibration series.  
222 Most of the  $\Delta$ 4-steroids, such as cortisol or testosterone, ionise more easily and so can be accurately  
223 quantified at low levels (0.03 – 0.15 nM). This allows for the quantification of testosterone in mCRPC  
224 patients (typically <0.5nM)<sup>41</sup>.  $\Delta$ 5-steroids such as DHEA and saturated steroids such as DHT are poor  
225 ionisers and quantification at lower concentrations is beyond the sensitivity of the mass spectrometer<sup>22</sup>.  
226 Like testosterone, DHT levels are suppressed in castrated patients and the concentrations in these  
227 patients could not be accurately assessed. DHEA levels in men decline with age<sup>41</sup>, and the mCRPC  
228 subjects in this study were older than the HC subjects. Consequently, values below the LLOQ were

229 detected in four mCRPC patients and were excluded from the analysis. Derivatization, for example to  
230 form an oxime, increases ionisability, and therefore sensitivity allowing low level quantification of  $\Delta$ 5-  
231 and 5 $\alpha$ -reduced steroids<sup>22</sup>. However, the derivatization method is not suited for routine clinical  
232 diagnostic measurements due to increased sample preparation time and cost. In addition to this,  
233 fragmentation produces multiple derivatives for some steroids adding to the complexity of the analysis.

234 Matrix effects and cross-reactivity are established sources of interference in steroid hormone profile  
235 studies with immunoassay and LC-MS/MS<sup>24-29</sup>. Previous studies have identified the type of blood sample  
236 tube as a potential source of interference. MSP tubes like BD Vacutainer® Barricor™ utilise mechanical  
237 separation of plasma, which makes them easily applicable, but the accuracy of steroid hormone  
238 measurements in these tubes has not been fully validated yet. Our study shows that multiplex steroid  
239 quantification in MSP samples is comparable to the serum collected with the reference tube, in line with  
240 a previous study that detected no bias versus gel-based plasma tubes using an immunoassay platform<sup>33</sup>.

241 The only significant difference between steroid measurements in MSP and serum related to DHEA.  
242 Quantification of DHEA at low concentrations with LC-MS/MS remains a challenge as its structure  
243 contributes to poor MS ionisation<sup>22,42</sup>. This challenge could be overcome by using a more sensitive mass  
244 spectrometer or with the use of derivatization. Prior to using MSP tubes for clinical studies, however, full  
245 validation considering accuracy, precision and recovery with larger sample size is recommended.

246 CS tubes are optimised for the measurement of circulating nucleic acids or tumour cells<sup>30,31</sup>. The use of  
247 this matrix for liquid biopsies has increased exponentially over the last years due to the successful  
248 genomic characterization of CTCs or free circulating nucleic acids, but no studies have investigated if  
249 plasma from CS tubes are suitable for quantification of circulating steroid hormone levels. Our  
250 experiments indicate that steroid measurements in CS samples are affected by a mild bias, which  
251 resulted in an approximate 8 – 21% decrease compared to serum. We observed similar effects in both

252 HCs and mCRPC subjects. CS tubes contain 300  $\mu$ L of Na<sub>2</sub>EDTA anticoagulant as well as an undisclosed  
253 preservative to stabilise cells in the sample. Due to the presence of the Na<sub>2</sub>EDTA there may be an  
254 inherent dilution of the sample, which amounts to approximately 3-4 % on a 7.5 – 10 mL volume. This  
255 dilution factor is insufficient to account for the difference in circulating steroid hormone levels however,  
256 and it is possible that other factors also contribute towards the observed difference.

257 This decrease was observed across a variety of different polarity steroids with different molecular  
258 weights. It is therefore unlikely that the preservative co-elutes with one of the steroids and suppresses  
259 the MS signal. Either there is an unidentified contaminant in the tubes which affects all steroids or the  
260 steroids themselves are being retained/bound to the tube itself. Steroids have been long recognised to  
261 bind to plastics<sup>43</sup>, which may contribute to the lower values in the CS samples.

262 Currently, CS tubes are most commonly utilised in oncological studies to obtain CTCs and ctDNA.  
263 Hormonal treatment options in breast- and prostate cancer involve potent suppression of oestrogens or  
264 androgens. For example, inhibition of testicular steroidogenesis by ADT will typically lower testosterone  
265 levels by >90 %<sup>11</sup>. Interpretation of such changes is unlikely to be affected by the difference observed in  
266 CS samples. Especially within the context of a single study the relative difference should affect all  
267 samples identically as long as a single collection tube is used. As such, the observed difference is  
268 acceptable for most clinical purposes, including the use of CS samples for steroid profiling in PC patients.  
269 Steroid profiles and analysis of CTCs or ctDNA investigation will decrease costs and reduce patient  
270 burden.

271 In conclusion, MSP samples are suitable for steroid quantification, including castrate range of  
272 androgens. Similarly, CS samples are suitable for steroid measurements, although there is a consistent  
273 bias of 8 - 21% lower steroid hormone levels. Therefore, all samples in a research study should be

274 collected in the same sample tubes to avoid potential variation due to effects from the tubes

275 themselves.

276

277 **References**

- 278 1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. *JAMA*  
279 2005;294:238-44.
- 280 2. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and  
281 overexpression of androgen receptor gene in hormone-refractory prostate cancer. *Cancer Res*  
282 2001;61:3550-5.
- 283 3. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate  
284 cancer. *Cancer Cell* 2010;18:11-22.
- 285 4. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal  
286 androgens to testosterone in androgen-independent prostate cancer. *Cancer Res* 2006;66:2815-25.
- 287 5. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in  
288 metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res*  
289 2008;68:4447-54.
- 290 6. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. *Clin*  
291 *Cancer Res* 2004;10:440-8.
- 292 7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after  
293 chemotherapy. *N Engl J Med* 2012;367:1187-97.
- 294 8. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic  
295 prostate cancer. *N Engl J Med* 2011;364:1995-2005.
- 296 9. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive  
297 Prostate Cancer. *N Engl J Med* 2017;377:352-60.
- 298 10. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in  
299 Metastatic Prostate Cancer. *N Engl J Med* 2019;381:121-31.
- 300 11. Snaterse G, Visser JA, Arlt W, Hofland J. Circulating steroid hormone variations throughout  
301 different stages of prostate cancer. *Endocr Relat Cancer* 2017;24:R403-R20.
- 302 12. Sakamoto S, Maimaiti M, Xu M, et al. Higher Serum Testosterone Levels Associated with  
303 Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. *J*  
304 *Clin Med* 2019;8.
- 305 13. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is  
306 highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol* 2009;27:3742-8.
- 307 14. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum  
308 testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-  
309 tandem mass spectrometry. *J Clin Endocrinol Metab* 2004;89:534-43.
- 310 15. Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-  
311 dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. *Clin Chem*  
312 2003;49:1381-95.
- 313 16. Handelsman DJ, Newman JD, Jimenez M, McLachlan R, Sartorius G, Jones GR. Performance of  
314 direct estradiol immunoassays with human male serum samples. *Clin Chem* 2014;60:510-7.
- 315 17. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid  
316 hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. *BMC*  
317 *Clin Pathol* 2014;14:33.
- 318 18. Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure  
319 steroid hormones today and tomorrow. *Eur J Endocrinol* 2015;173:D1-12.
- 320 19. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and  
321 the management of the HPA axis. *Rev Endocr Metab Disord* 2013;14:143-57.

- 322 20. Arlt W, Lang K, Sitch AJ, et al. Steroid metabolome analysis reveals prevalent glucocorticoid  
323 excess in primary aldosteronism. *JCI Insight* 2017;2.
- 324 21. Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting  
325 malignancy in adrenal tumors. *J Clin Endocrinol Metab* 2011;96:3775-84.
- 326 22. Hakkinen MR, Murtola T, Voutilainen R, et al. Simultaneous analysis by LC-MS/MS of 22  
327 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum  
328 and prostate tissue. *J Pharm Biomed Anal* 2019;164:642-52.
- 329 23. Storbeck KH, Schiffer L, Baranowski ES, et al. Steroid metabolome analysis in disorders of  
330 adrenal steroid biosynthesis and metabolism. *Endocr Rev* 2019.
- 331 24. Coburn SB, Stanczyk FZ, Falk RT, et al. Comparability of serum, plasma, and urinary estrogen and  
332 estrogen metabolite measurements by sex and menopausal status. *Cancer Causes Control* 2019;30:75-  
333 86.
- 334 25. Hepburn S, Wright MJ, Boyder C, et al. Sex steroid hormone stability in serum tubes with and  
335 without separator gels. *Clin Chem Lab Med* 2016;54:1451-9.
- 336 26. Raff H, Sluss PM. Pre-analytical issues for testosterone and estradiol assays. *Steroids*  
337 2008;73:1297-304.
- 338 27. Morovat A, James TS, Cox SD, et al. Comparison of Bayer Advia Centaur immunoassay results  
339 obtained on samples collected in four different Becton Dickinson Vacutainer tubes. *Ann Clin Biochem*  
340 2006;43:481-7.
- 341 28. Smets EM, Dijkstra-Lagemaat JE, Blankenstein MA. Influence of blood collection in plastic vs.  
342 glass evacuated serum-separator tubes on hormone and tumour marker levels. *Clin Chem Lab Med*  
343 2004;42:435-9.
- 344 29. Schouwens S, Brandt I, Willemse J, et al. Influence of separator gel in Sarstedt S-Monovette(R)  
345 serum tubes on various therapeutic drugs, hormones, and proteins. *Clin Chim Acta* 2012;413:100-4.
- 346 30. Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free  
347 DNA and circulating tumour cells isolated from the same preserved whole blood sample. *Mol Oncol*  
348 2016;10:566-74.
- 349 31. van Dessel LF, Beije N, Helmijr JC, et al. Application of circulating tumor DNA in prospective  
350 clinical oncology trials - standardization of preanalytical conditions. *Mol Oncol* 2017;11:295-304.
- 351 32. van Dessel LF, van Riet J, Smits M, et al. The genomic landscape of metastatic castration-  
352 resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. *Nat*  
353 *Commun* 2019;10:5251.
- 354 33. Fournier JE, Northrup V, Clark C, et al. Evaluation of BD Vacutainer(R) Barricor blood collection  
355 tubes for routine chemistry testing on a Roche Cobas(R) 8000 Platform. *Clin Biochem* 2018;58:94-9.
- 356 34. O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in  
357 polycystic ovary syndrome: the utility of serum androstenedione. *J Clin Endocrinol Metab* 2014;99:1027-  
358 36.
- 359 35. O'Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 Steroids Are the  
360 Predominant Androgens in Polycystic Ovary Syndrome. *J Clin Endocrinol Metab* 2017;102:840-8.
- 361 36. Quanson JL, Stander MA, Pretorius E, Jenkinson C, Taylor AE, Storbeck KH. High-throughput  
362 analysis of 19 endogenous androgenic steroids by ultra-performance convergence chromatography  
363 tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016;1031:131-8.
- 364 37. van der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical  
365 steroidogenesis in vitro. *J Endocrinol* 2012;215:403-12.
- 366 38. Prete A, Taylor AE, Bancos I, et al. Prevention of Adrenal Crisis: Cortisol Responses to Major  
367 Stress Compared to Stress Dose Hydrocortisone Delivery. *J Clin Endocrinol Metab* 2020;105.
- 368 39. Juhlen R, Idkowiak J, Taylor AE, et al. Role of ALADIN in human adrenocortical cells for oxidative  
369 stress response and steroidogenesis. *PLoS One* 2015;10:e0124582.

- 370 40. Agency EM. Guideline on Bioanalytical Method Validation. 2011.  
371 41. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and  
372 therapeutic implications. *Endocr Rev* 2005;26:833-76.  
373 42. Keski-Rahkonen P, Huhtinen K, Poutanen M, Auriola S. Fast and sensitive liquid chromatography-  
374 mass spectrometry assay for seven androgenic and progestagenic steroids in human serum. *J Steroid*  
375 *Biochem Mol Biol* 2011;127:396-404.  
376 43. Bruning PF, Jonker KM, Boerema-Baan AW. Adsorption of steroid hormones by plastic tubing. *J*  
377 *Steroid Biochem* 1981;14:553-5.

378

379

380 **Acknowledgements**

381 Funding for this project was provided by the Daniel den Hoed foundation.

382 The authors thank the volunteers and patients who made this study possible.

383 **Author Information**

384 These authors contributed equally: Gido Snaterse and Lisanne F van Dessel.

385 **Author Contributions**

386 G.S. performed the LC-MS/MS experiments, data analysis, prepared figures/tables and wrote the  
387 manuscript. L.F.D. collected the patient samples, performed data analysis, prepared figures/tables and  
388 wrote the manuscript. A.E.T. oversaw the LC-MS/MS experiments and analysis of the data, and critical  
389 revision of the manuscript. W.A. was involved in interpretation of the data and critical revision of the  
390 manuscript. M.P.L. was involved in the design of the work, collection of the samples and critical revision  
391 of the manuscript. J.A.V and J.H. were involved in the design of the work, interpretation of the data, and  
392 critical revision of the manuscript.

393 All authors reviewed and approved the final version of the manuscript.

394 **Corresponding author**

395 Correspondence to Johannes Hofland.

396 **Conflict of Interest**

397 M.P.L. is the recipient of grants of Sanofi, Johnson & Johnson and Astellas. Other authors did not declare  
398 a conflict of interests.

399 **Data Availability**

400 The datasets generated during and/or analysed during the current study are available from the  
401 corresponding author on reasonable request.

402

403 **Table 1 – Characteristics of HCs and mCRPC patients**

404 *Abbreviations:* HCs - healthy controls, mCRPC – metastatic castration-resistant prostate cancer

	<b>HCs</b>	<b>mCRPC patients</b>
<b>N</b>	10	10
<b>Age (median (range))</b>	32 (25 - 56)	64 (59 - 76)
<b>Androgen Deprivation Therapy (n)</b>		<b>10</b>
Leuproreline		4
Gosereline		4
Bilateral orchiectomy		2
<b>Current second-line treatment (n)</b>		<b>6</b>
Enzalutamide		3
Apalutamide		1
Abiraterone + Prednisone		1
Prednisone		1

405

406 **Table 2 – Relative differences in CS and MSP samples compared to serum samples.**

407 Relative differences are shown as mean  $\pm$  SD. Statistical comparison was performed by repeated  
408 measurement 1-way ANOVA with post-hoc Dunnett’s Test. \*p<0.05, \*\* p<0.01, \*\*\*p<0.001.

409 Abbreviations: CS – CellSave Preservative, DHEA – dehydroepiandrosterone, DHT – 5 $\alpha$ -  
410 dihydrotestosterone, HC – Healthy Control, mCRPC – metastatic castration-resistant prostate cancer,  
411 MSP – mechanically separated plasma

	Healthy Controls (n = 10)			mCRPC (n = 10)		
	Serum Range nmol/L	CS Rel. Difference mean (SD) %	MSP Rel. Difference mean (SD) %	Serum Range nmol/L	CS Rel. Difference mean (SD) %	MSP Rel. Difference mean (SD) %
Corticosterone	2.32 - 32.71	-20.08 (16.6) **	2.6 (11)	0.55 - 25.34	-12.3 (13.3) *	-2.8 (9.8)
17-hydroxyprogesterone	0.37 - 3.75	-14.4 (15.3) *	3.16 (16.26)	0.1 - 1.75	-3.2(24.1)	-2.2 (9.4)
Cortisol	149.1 - 475.7	-13.7 (6.1) ***	-0.14 (3.5)	7.43 - 504.6	-12.7 (17.9) **	-1.3 (16.1)
Cortisone	36.35 - 79.4	-10.8 (6.3) ***	-2 (9.2)	0.1 - 80.81	-17.9 (17.2) **	-1.5 (10.5)
DHEA	0.69 - 36.14	-0.17 (18.8)	28.7 (46.6)*	<LOQ - 1.7	-17.7 (16.5)	6.0 (12.2)
Androstenedione	2.33 - 6.05	-15.85 (13.5) **	6.9 (9.5)	0.48 - 3.19	- 21.2 (14.01) **	6.34 (10.4)
Testosterone	7.47 - 17.74	-11.48 (2.8) ***	0.82 (4.7)	0.13 - 0.78	-16.9 (24.3) *	-2.8 (30.6)
DHT	0.66 - 1.64	-11.26 (29.2)	-3.5 (30.4)	<LOQ	<LOQ	<LOQ

413 **Figure 1. CS and MSP samples compared to serum samples in healthy controls and mCRPC patients.**

414 Steroid concentrations from serum, CS and MSP samples obtained from ten HCs and ten mCRPC patients  
415 measured by LC-MS/MS. Bland-Altman plots show the relative difference of CS (black) and MSP (gray)  
416 measurements compared to serum. Continuous lines show the mean difference and dotted lines show  
417 the upper- and lower limits of the 95% confidence interval.

418 *Abbreviations:* CS – CellSave Preservative, DHEA – dehydroepiandrosterone, HC – Healthy Control,  
419 mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically separated plasma

420

421 **Figure 2 – Circulating steroid concentrations in serum of HCs and mCRPC subjects.**

422 Steroid hormone concentrations in healthy controls (n = 10) and mCRPC patients (n = 10). Four patients  
423 received no additional treatment, four received antiandrogens (enzalutamide (n=3) or apalutamide  
424 (n=1)), one received abiraterone and prednisone and one received prednisone. Line and error represent  
425 mean  $\pm$  SEMs.









426 *Abbreviations:* 17OHP – 17-hydroxyprogesterone, A4 – androstenedione, B – corticosterone, DHEA –  
427 dehydroepiandrosterone, mCRPC – metastatic castration-resistant prostate cancer, E – cortisone, F –  
428 cortisol, T – testosterone

429


430 **Figure 3 – Correlations between CS samples and MSP samples with serum samples.**

431 Deming regression analysis between measurements from serum and CS samples and between serum  
432 and MSP samples in HC and mCRPC patients combined. Corticosterone, DHEA and testosterone values  
433 did not pass normality testing (D'Agostino and Pearson), but did so after logarithmic transformation.  
434 Regression equations for testosterone are presented separately for HCs and mCRPC patients due to the  
435 bimodal distribution resulting from ADT. For DHT, only HC values were used as values in CRPC patients  
436 were below the LLOQ.


437 *Abbreviations:* ADT – androgen deprivation therapy, CS – CellSave Preservative, DHEA –  
438 dehydroepiandrosterone, DHT – Dihydrotestosterone, HC – healthy controls, LLOQ – lower limit of  
439 quantification, mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically separated  
440 plasma.




● CS  
● MSP




### Corticosterone




### 17-hydroxyprogesterone




### Cortisol




### Cortisone




### DHEA




### Androstenedione



### Testosterone



### DHT



- CS
- MSP